Other Clinical Trial - A Rollover Study of ARRY-371797 in Patients With

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02057341` - A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy	Phase 2

NCT number	NCT02351856
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 2
Start date	February 2, 2015
Completion date	December 21, 2020

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms